(0.23%) 5 534.25 points
(0.23%) 39 561 points
(0.23%) 19 974 points
(0.66%) $82.08
(-2.00%) $2.55
(0.29%) $2 346.50
(0.02%) $29.57
(-0.54%) $996.50
(-0.26%) $0.931
(-0.28%) $10.65
(-0.16%) $0.789
(2.08%) $87.51
Live Chart Being Loaded With Signals
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide...
Stats | |
---|---|
今日成交量 | 3.21M |
平均成交量 | 1.65M |
市值 | 10.18B |
EPS | $-0.550 ( Q3 | 2024-05-08 ) |
下一个收益日期 | ( $0.460 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.68 (Sector) 49.64 (Industry) 35.32 |
ATR14 | $0.0240 (0.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-04 | Hopson Ricky | Sell | 1 401 | Common Stock |
2024-03-15 | Gunther Scott | Sell | 387 | Common Stock |
2024-01-25 | Kreuzburg Christa | Sell | 523 | Common Stock |
2024-01-16 | Hatzfeld Michael | Buy | 6 071 | Common Stock |
2024-01-16 | Hatzfeld Michael | Buy | 3 981 | Options to purchase Common Stock |
INSIDER POWER |
---|
69.89 |
Last 95 transactions |
Buy: 316 064 | Sell: 55 780 |
音量 相关性
Catalent Inc 相关性 - 货币/商品
Catalent Inc 财务报表
Annual | 2023 |
营收: | $4.28B |
毛利润: | $1.06B (24.79 %) |
EPS: | $-1.280 |
FY | 2023 |
营收: | $4.28B |
毛利润: | $1.06B (24.79 %) |
EPS: | $-1.280 |
FY | 2022 |
营收: | $4.83B |
毛利润: | $1.64B (33.97 %) |
EPS: | $2.74 |
FY | 2021 |
营收: | $4.00B |
毛利润: | $1.35B (33.82 %) |
EPS: | $3.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Catalent Inc
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。